ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Administrative Data"

  • Abstract Number: 0750 • ACR Convergence 2022

    Quality Improvement Project to Increase the Rate of Vaccination with Pneumococcal Vaccines (PCV13 prime-PPSV23 Boost Strategy) Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Within Nationwide Health Organization

    Victoria Furer, Hagit Sarbagil-Maman and Ori Elkayam, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are susceptible for pneumococcal disease. Two vaccines against S. pneumoniae are currently recommended for use: a 23-valent…
  • Abstract Number: 2062 • ACR Convergence 2022

    Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US

    Sandra Sze-jung Wu1, Allison Perry2, Nicole Zimmerman3, Helen Varker4, Rich Bizier4, Liisa Palmer4, Christine Dube5 and Gary Bryant6, 1AstraZeneca, Hockessin, DE, 2IBM Watson Health, New York, NY, 3IBM Watson Health, Chagrin Falls, OH, 4Merative, Cambridge, MA, 5AstraZeneca, Torrington, CT, 6AstraZeneca, New Castle, DE

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex disease with multisystem inflammation resulting in variable clinical manifestations. As a result, predicting the occurrence of an…
  • Abstract Number: 0068 • ACR Convergence 2022

    Differential Diagnostic Coding Patterns and Associated Sociodemographic Factors in Childhood-Onset Lupus Nephritis

    Emily Smitherman1, Rouba Chahine1, Aimee Hersh2 and Jeffrey Curtis3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Utah, Salt Lake City, UT, 3University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Disparities in long-term kidney outcomes have been documented in patients with childhood-onset systemic lupus erythematosus (cSLE) complicated by lupus nephritis (LN). However, there remains…
  • Abstract Number: 0760 • ACR Convergence 2022

    Prevalence of Autoimmune Conditions in Metastatic Melanoma Patients Starting Checkpoint Inhibitors

    Alexandra Ladouceur1, Marina Amaral De Avila Machado2, Marie Hudson1, Cristiano Moura3 and Sasha Bernatsky3, 1McGill University, Montréal, QC, Canada, 2Research Institute of McGill University Health Center, Montréal, QC, Canada, 3Research Institute of the McGill University Health Centre, Montréal, QC, Canada

    Background/Purpose: Since patients with pre-existing autoimmune conditions are commonly excluded from clinical trials with immune checkpoint inhibitors (ICI), we aimed to describe the characteristics of…
  • Abstract Number: 2080 • ACR Convergence 2022

    Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample

    Rashmi Dhital1, Monica Guma2, Brian Pedersen1, Ashbina Pokharel3 and Kenneth Kalunian4, 1UC San Diego, San Diego, CA, 2UCSD, La Jolla, CA, 3William Beaumont Hospital, Royal Oak, MI, 4University of California San Diego, La Jolla, CA

    Background/Purpose: Patients with autoimmune rheumatic diseases presenting to the emergency department (ED) often have multi-organ pathology. SLE patients may be particularly prone to ED visits…
  • Abstract Number: 0070 • ACR Convergence 2022

    Post-operative Delirium and Cognitive Impairment: An Analysis of Predictors and 120-day Outcomes in England Using the National Hip Fracture Database (NHFD)

    Samuel Hawley1, Dominic Inman2, Celia Gregson1, Michael Whitehouse1, Antony Johansen3 and Andrew Judge1, 1University of Bristol, Bristol, United Kingdom, 2Northumbria Healthcare NHS Foundation Trust, Northumbria, United Kingdom, 3Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Post-operative delirium and cognitive impairment are common after hip fracture. We set out to identify risk factors and examine the association with returning home…
  • Abstract Number: 0826 • ACR Convergence 2022

    Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Treatment in Patients with Adult Still’s Disease: An Analysis of a Japanese Claims Database

    Yuko Kaneko1, Hideto Kameda2, Kei Ikeda3, Katsuhisa Yamashita4, Ryoto Ozaki5 and Yoshiya Tanaka6, 1Keio University School of Medicine, Tokyo, Japan, 2Toho University, Tokyo, Japan, 3Chiba University Hospital, Chiba, Japan, 4Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan, 5Chugai Pharmaceutical Co. Ltd., Tokyo, Japan, 6University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan

    Background/Purpose: Adult Still's disease (ASD), including adult-onset Still's disease and carry-over systemic juvenile idiopathic arthritis (sJIA), is treated with glucocorticoids (GC) with or without immunosuppressive…
  • Abstract Number: 2121 • ACR Convergence 2022

    Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database

    Laura Pina Vegas1, Emilie sbidian2 and Pascal Claudepierre3, 1Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, 2Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, 3Paris Est Creteil University, Creteil, France

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed,…
  • Abstract Number: 0071 • ACR Convergence 2022

    Workforce Changes and Characteristics of Adult Rheumatologists in a United States Medicare Claims Analysis

    Melissa Mannion1, Fenglong Xie1, John FitzGerald2, Amy Mudano3, Zihan Wan1 and Jeffrey Curtis4, 1University of Alabama at Birmingham, Birmingham, AL, 2University of California Los Angeles, Los Angeles, CA, 3Illumination Health, Hoover, AL, 4University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Prior studies have projected inadequate growth in the rheumatology provider workforce to keep up with population demand. The objective of this project was to…
  • Abstract Number: 0887 • ACR Convergence 2022

    Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necrosis Factor-α Inhibitors and Tocilizumab as the First-line Biological Treatment in Patients with Rheumatoid Arthritis Using the Korean Health Insurance Review and Assessment Service Database

    Byung Wook Song, Dong-Hyuk Moon, Aran Kim and Seung-Geun Lee, Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea

    Background/Purpose: Drug persistence represents long-term therapeutic performance in real clinical setting and tuberculosis (TB) is one of the most important adverse events following biological treatments…
  • Abstract Number: 2192 • ACR Convergence 2022

    Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability

    Leah K. Flatman1, Yvan St. Pierre2, Isabelle Malhamé3, Olga Basso1, Anick Berard4, Sasha Bernatsky2 and Evelyne Vinet3, 1McGill University, Montréal, QC, Canada, 2Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 3McGill University Health Centre, Montréal, QC, Canada, 4University of Montreal, Montréal, QC, Canada

    Background/Purpose: During pregnancy, best practice guidelines suggest discontinuing tumour necrosis factor inhibitors (TNFi) with high placental transfer before or during the third trimester if the…
  • Abstract Number: 0074 • ACR Convergence 2022

    Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US

    Prajakta Masurkar1, Jennifer Reckleff2, Nicole Princic3, Brendan Limone4, Hana Schwartz4, Elaine Karis5, Eric Zollars6, Bradley Stolshek5 and Karen Costenbader7, 1Amgen, Wylie, TX, 2Amgen, Westlake Village, CA, 3IBM Watson Health, Reading, MA, 4IBM Watson Health, Bethesda, MD, 5Amgen, Inc., Thousand Oaks, CA, 6Amgen, Newbury Park, CA, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: SLE treatment is complex, with a wide variety of medications commonly prescribed. Limited evidence exists in the literature with respect to treatment patterns, HCRU…
  • Abstract Number: 0925 • ACR Convergence 2022

    Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis

    Mengdong He1, Yvonne Lee2, Yinzhu Jin3, Rishi Desai3, Seanna Vine3 and Seoyoung Kim3, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2Northwestern University, Chicago, IL, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…
  • Abstract Number: 2197 • ACR Convergence 2022

    Unmet Need in Systemic Lupus Erythematosus (SLE) Therapy: High Corticosteroid Use and Poor Adherence and Persistence to SLE Treatments in the US

    Prajakta Masurkar1, Jennifer Reckleff2, Nicole Princic3, Brendan Limone4, Hana Schwartz4, Elaine Karis5, Eric Zollars6, Bradley Stolshek5 and Karen Costenbader7, 1Amgen, Wylie, TX, 2Amgen, Westlake Village, CA, 3IBM Watson Health, Reading, MA, 4IBM Watson Health, Bethesda, MD, 5Amgen, Inc., Thousand Oaks, CA, 6Amgen, Newbury Park, CA, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Poor treatment adherence and persistence is an ongoing problem among SLE patients due to complex regimens and may lead to frequent use of high-dose…
  • Abstract Number: 0075 • ACR Convergence 2022

    Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis

    Yuen Tsang1, Marjolaine Gauthier-Loiselle2, Vienica Funtanilla3, Hayley Germack3, Ameur Manceur4, Stephanie Liu2, Martin Cloutier2, Patrick Lefebvre2 and Sumeet Panjabi5, 1Janssen Scientific Affairs, LLC., Sacramento, CA, 2Analysis Group, Inc., Montréal, QC, Canada, 3Janssen Scientific Affairs, LLC, Titusville, NJ, 4Analysis Group, Inc, Boston, MA, 5Analysis Group, Inc., Titusville, NB, Canada

    Background/Purpose: Connective tissue disorders (CTDs) are the most frequent diseases associated with pulmonary arterial hypertension (PAH), accounting for 11% – 28% of PAH cases. A…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology